Diabetes

Natural product-based exercise mementics therapy for Metabolic disease: 18β-Glycyrrhetinic acid [(18β-GA) Enoxolone], isolated from glycyrrhiza glabra/Licorice, increases PPARδ  and Foxo1 levels, inhibits glucose catabolism, preserves glucose levels, stimulates FA catabolism, delays the onset of hypoglycemia and boosts endurance exercise via down regulation of its target gene, 27/January/2018, 11.41 pm
Natural product-based exercise mementics therapy for Metabolic disease: 18β-Glycyrrhetinic acid [(18β-GA) Enoxolone], isolated from glycyrrhiza glabra/Licorice, increases PPARδ  and Foxo1 levels, inhibits glucose catabolism, preserves glucose levels, stimulates FA catabolism, delays the onset of hypoglycemia and boosts endurance exercise via down regulation of its target gene, 27/January/2018, 11.41 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Department of Molecular Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA shows that “CRY1/2 Selectively Repress…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: Lanzoprazole(brand name: Prevacid), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 27/January/2018, 11.25 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: Lanzoprazole(brand name: Prevacid), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 27/January/2018, 11.25 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour and metabolism by synthetic…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pantoprazole  and Pyridoxamine (PAP) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 26/January/2017, 11.22 pm
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pantoprazole  and Pyridoxamine (PAP) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 26/January/2017, 11.22 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Omeprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 11.08 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Omeprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 11.08 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Lansoprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 12.11 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Lansoprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 12.11 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for Diabetic nephropathy (DN): Valsartan(Trade name: Diovan), an angiotensin converting enzyme inhibitor used in the treatment of hypertension, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 23/January/2018, 11.59 pm
Molecular therapy for Diabetic nephropathy (DN): Valsartan(Trade name: Diovan), an angiotensin converting enzyme inhibitor used in the treatment of hypertension, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 23/January/2018, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more
Start Typing